Once-a-day Tacrolimus Conversion Study: The OneTAC Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02545972

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Newark Beth Israel Medical Center (from the registry)
Registry
  • NCT NCT02545972
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02545972. Allocation not applicable; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2018-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
Acronym
OneTAC
Condition
Heart Failure
Intervention (Drug)
tacrolimus extended release
Lead sponsor
Newark Beth Israel Medical Center (class: other)

Record details

Record id
cardio:ct-nct02545972
Content hash
567254fde4b9353a673baac74b922ddb42d121c9f23ccd2446721451d865c73b